AiPD: Autoinhibited Protein Database

P35232

Gene name	PHB1
Protein name	Prohibitin 1
Names
Species	Homo sapiens (Human)
KEGG Pathway	hsa:5245
EC number
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

163-249 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

163-249 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

1 structures for P35232

Entry ID	Method	Resolution	Chain	Position	Source
AF-P35232-F1	Predicted				AlphaFoldDB

160 variants for P35232

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
CA400143309 rs1389629518	2	A>T		No	ClinGen gnomAD
CA291463722 rs935358299	4	K>T		No	ClinGen Ensembl
CA400143269 rs1485383051	5	V>A		No	ClinGen TOPMed gnomAD
rs763780559 CA291463720	6	F>L		No	ClinGen TOPMed
rs755901686 CA8638385	9	I>F		No	ClinGen ExAC gnomAD
rs755901686 CA400143230	9	I>V		No	ClinGen ExAC gnomAD
rs1390743070 CA400143211	10	G>V		No	ClinGen gnomAD
rs902509386 CA400143189	12	F>C		No	ClinGen Ensembl
rs902509386 CA291463716	12	F>S		No	ClinGen Ensembl
CA8638382 rs561121669	15	A>V		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA291463710 rs11658876	17	A>S		No	ClinGen Ensembl
CA291463707 rs949350204	17	A>V		No	ClinGen Ensembl
rs751042596 CA8638381	18	V>L		No	ClinGen ExAC gnomAD
rs765685663 CA8638380	19	A>S		No	ClinGen ExAC gnomAD
rs1218918792 CA400143094	21	G>V		No	ClinGen gnomAD
CA400143087 rs1229985221	22	V>M		No	ClinGen TOPMed gnomAD
CA8638378 rs754267744	26	A>D		No	ClinGen ExAC gnomAD
rs754267744 CA400143038	26	A>V		No	ClinGen ExAC gnomAD
rs754355612 CA8638360	31	D>E		No	ClinGen ExAC gnomAD
rs1433931640 CA400142881	32	A>T		No	ClinGen TOPMed
CA8638357 rs753054107	41	R>Q	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
CA8638356 rs767677971	43	R>C		No	ClinGen ExAC TOPMed gnomAD
CA291463427 rs767677971	43	R>G		No	ClinGen ExAC TOPMed gnomAD
CA8638355 rs2233665	43	R>H		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA8638354 rs2233665	43	R>L		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
rs1456528524 CA400142791	46	Q>P		No	ClinGen gnomAD
CA291463421 rs757863990	47	D>E		No	ClinGen Ensembl
rs766557694 CA8638353	47	D>N		No	ClinGen ExAC TOPMed gnomAD
CA291463419 rs930087263	48	I>T		No	ClinGen TOPMed
rs1597828925 CA400142779	48	I>V		No	ClinGen Ensembl
CA400142764 rs1183862410	50	V>A		No	ClinGen gnomAD
rs201359263 CA291463415	51	G>A		No	ClinGen gnomAD
rs201359263 CA291463417	51	G>E		No	ClinGen gnomAD
rs201359263 CA291463413	51	G>V		No	ClinGen gnomAD
rs1597828902 CA400142755	52	E>G		No	ClinGen Ensembl
rs1597828891 CA400142745	54	T>A		No	ClinGen Ensembl
rs763072596 CA8638352	54	T>S		No	ClinGen ExAC gnomAD
CA400142731 rs1245614422	56	F>L		No	ClinGen gnomAD
rs769816421 CA400142704	59	P>L		No	ClinGen ExAC gnomAD
rs769816421 CA8638350	59	P>Q		No	ClinGen ExAC gnomAD
CA8638349 rs747919114	60	W>C		No	ClinGen ExAC gnomAD
rs370766193 CA8638348	61	V>A		No	ClinGen ESP ExAC gnomAD
rs746659527 CA8638346	62	Q>P		No	ClinGen ExAC gnomAD
CA400142664 rs746659527	62	Q>R		No	ClinGen ExAC gnomAD
rs1597828849 CA400142650	63	K>T		No	ClinGen Ensembl
CA400142638 rs1374341000	64	P>Q		No	ClinGen gnomAD
rs748212379 CA291463401	68	D>N		No	ClinGen TOPMed gnomAD
CA8638345 rs779623438	69	C>R		No	ClinGen ExAC gnomAD
CA8638344 rs757906969	70	R>C	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
CA8638343 rs745340447	70	R>H		No	ClinGen ExAC TOPMed gnomAD
CA291463391 rs945635098	72	R>*		No	ClinGen TOPMed
CA8638342 rs778272458	72	R>Q		No	ClinGen ExAC TOPMed gnomAD
rs367962991 CA8638341	73	P>L		No	ClinGen ESP ExAC gnomAD
rs1434337536 CA400142531	73	P>S		No	ClinGen gnomAD
rs1270990361 CA400142519	74	R>C		No	ClinGen TOPMed
CA400142517 rs1161179565	74	R>H		No	ClinGen TOPMed gnomAD
rs781612334 CA8638339	80	T>S		No	ClinGen ExAC gnomAD
VAR_006479 CA291462846 rs121918373	88	V>A	a breast cancer sample; somatic mutation [UniProt]	No	ClinGen UniProt Ensembl dbSNP
rs771661758 CA8638325	89	N>S		No	ClinGen ExAC gnomAD
rs770266294 COSM980790 CA8638322	93	R>C	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD
CA400141739 rs1160485484	93	R>H		No	ClinGen TOPMed
CA400141716 rs373869165	96	F>L		No	ClinGen 1000Genomes ExAC TOPMed gnomAD
CA400141713 rs1444408475	97	R>Q		No	ClinGen gnomAD
TCGA novel CA400141714 rs1597827059	97	R>W	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA Ensembl
rs1281059238 CA400141709	98	P>A		No	ClinGen TOPMed gnomAD
CA8638318 COSM980789 rs751935018	100	A>T	endometrium [Cosmic]	No	ClinGen cosmic curated ExAC TOPMed gnomAD
rs1378160082 CA400141669	104	P>R		No	ClinGen gnomAD
CA291462830 rs954452399	104	P>S		No	ClinGen TOPMed gnomAD
rs954452399 CA291462832	104	P>T		No	ClinGen TOPMed gnomAD
CA8638317 rs780447025	105	R>C	Variant assessed as Somatic; 4.621e-05 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
COSM980788 rs121918372 CA8638316 VAR_006480	105	R>H	Variant assessed as Somatic; 0.0 impact. endometrium a breast cancer sample; somatic mutation [NCI-TCGA, Cosmic, UniProt]	No	ClinGen cosmic curated UniProt ExAC NCI-TCGA TOPMed dbSNP gnomAD
rs199792568 CA291462824	108	T>S		No	ClinGen 1000Genomes
CA291462818 rs1049515	111	G>E		No	ClinGen Ensembl
CA400141603 rs1283260225	114	Y>C		No	ClinGen TOPMed
CA8638313 COSM1195620 rs761740286	115	D>N	lung [Cosmic]	No	ClinGen cosmic curated ExAC gnomAD
TCGA novel	115	D>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs763896962 CA8638311	117	R>S		No	ClinGen ExAC gnomAD
rs929052861 CA400141579	118	V>L		No	ClinGen gnomAD
CA291462808 rs929052861	118	V>M		No	ClinGen gnomAD
rs1597826965 CA400141574	119	L>M		No	ClinGen Ensembl
TCGA novel	120	P>S	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs775240348 CA8638309	126	I>F		No	ClinGen ExAC gnomAD
TCGA novel	127	L>P	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA8638306 rs773904635	130	V>A		No	ClinGen ExAC gnomAD
rs759272172 COSM980786 CA8638289	133	R>C	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ExAC NCI-TCGA gnomAD
rs369362522 CA8638288	133	R>H		No	ClinGen ESP ExAC TOPMed gnomAD
rs369362522 CA400141461	133	R>L		No	ClinGen ESP ExAC TOPMed gnomAD
rs1267343521 CA400141418	137	G>E		No	ClinGen TOPMed gnomAD
CA400141373 rs1274864003	142	Q>K		No	ClinGen gnomAD
TCGA novel	144	E>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs762550456 CA8638286	145	L>V		No	ClinGen ExAC gnomAD
CA400141319 rs1328906761	146	V>G		No	ClinGen TOPMed
rs769247857 CA8638284	147	S>P		No	ClinGen ExAC gnomAD
CA400141305 rs1230226561	148	R>G		No	ClinGen TOPMed
rs1279427254 CA400141298	148	R>M		No	ClinGen TOPMed
CA8638283 rs140693016	148	R>S		No	ClinGen ESP ExAC gnomAD
rs1597826692 CA400141276	150	V>G		No	ClinGen Ensembl
TCGA novel	150	V>L	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA400141284 rs1443836701	150	V>M		No	ClinGen gnomAD
CA8638280 rs746195052	152	D>N		No	ClinGen ExAC TOPMed gnomAD
CA8638278 rs757398416	153	D>N		No	ClinGen ExAC gnomAD
rs777707941 CA400141215	155	T>I		No	ClinGen ExAC gnomAD
rs777707941 CA8638276	155	T>R		No	ClinGen ExAC gnomAD
CA8638274 rs752641520	156	E>D		No	ClinGen ExAC gnomAD
rs767379834 CA8638273	157	R>*		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	157	R>P	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs561576696 CA8638272	158	A>V		No	ClinGen 1000Genomes ExAC gnomAD
rs766107160 CA8638270	159	A>T		No	ClinGen ExAC gnomAD
CA400141154 rs1232125222	159	A>V		No	ClinGen gnomAD
rs1402273692 CA400141146	160	T>N		No	ClinGen gnomAD
TCGA novel	162	G>E	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs762483899 CA8638269	162	G>W		No	ClinGen ExAC gnomAD
TCGA novel	164	I>F	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	167	D>G	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs772847607 CA400141029	168	V>L		No	ClinGen ExAC TOPMed gnomAD
CA8638268 COSM980784 rs772847607	168	V>M	Variant assessed as Somatic; 0.0 impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD
CA400140429 rs1314790132	171	T>S		No	ClinGen gnomAD
rs1435444564 CA400140417	172	H>Y		No	ClinGen gnomAD
CA8638251 rs750057673	174	T>A		No	ClinGen ExAC gnomAD
rs764942843 CA8638250	174	T>I		No	ClinGen ExAC gnomAD
rs761430339 CA8638249	175	F>C		No	ClinGen ExAC
CA8638247 rs768177920	176	G>R		No	ClinGen ExAC gnomAD
CA400140319 rs1567715738	180	T>A		No	ClinGen Ensembl
CA291462227 rs374136586	182	A>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen ESP NCI-TCGA TOPMed gnomAD
CA8638242 rs773341333	192	E>K		No	ClinGen ExAC TOPMed gnomAD
CA400140111 rs1240696874	195	R>K		No	ClinGen gnomAD
rs1342104712 CA400140021	201	E>D		No	ClinGen gnomAD
rs1376619438 CA400139932	206	Q>R		No	ClinGen gnomAD
CA291461896 rs747594398	209	A>T		No	ClinGen Ensembl
COSM262915 CA8638212 rs377541756	209	A>V	Variant assessed as Somatic; 0.0 impact. large_intestine endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated ESP ExAC NCI-TCGA gnomAD
rs1214737373 CA400139838	213	S>F		No	ClinGen gnomAD
rs1420781936 CA400139758	222	E>A		No	ClinGen gnomAD
rs1351489131 CA400139743	224	I>M		No	ClinGen gnomAD
rs1231919032 CA400139721	228	L>V		No	ClinGen gnomAD
CA400139712 rs1373106132	229	A>V		No	ClinGen gnomAD
CA291461886 rs865787357	230	T>I		No	ClinGen Ensembl
CA400139692 rs1340652815	233	D>Y		No	ClinGen TOPMed
rs776845152 CA8638203	237	E>D		No	ClinGen ExAC gnomAD
rs137958073 CA8638204	237	E>K		No	ClinGen ESP ExAC TOPMed gnomAD
COSM707013 rs1170298277 CA400139654	239	R>H	lung [Cosmic]	No	ClinGen cosmic curated gnomAD
rs1486349761 CA400139619	244	A>V		No	ClinGen TOPMed
CA291461869 rs988622651	248	A>S		No	ClinGen TOPMed gnomAD
CA400139595 rs988622651	248	A>T		No	ClinGen TOPMed gnomAD
CA400139591 rs1277922087	248	A>V	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs745786936 CA8638198	250	Q>R		No	ClinGen ExAC gnomAD
CA400139561 rs1414203733	253	R>C		No	ClinGen TOPMed
COSM980782 CA8638196 rs770849761	253	R>H	endometrium [Cosmic]	No	ClinGen cosmic curated ExAC TOPMed gnomAD
rs1271777917 CA400139551	255	R>Q		No	ClinGen gnomAD
CA8638195 rs749048541	255	R>W		No	ClinGen ExAC gnomAD
rs1346579473 CA400139537	257	I>V		No	ClinGen TOPMed
rs1597823463 CA400139532	258	T>P		No	ClinGen Ensembl
rs1597823460 CA400139522	259	Y>S		No	ClinGen Ensembl
rs375008157 CA8638194	262	A>V		No	ClinGen ESP ExAC gnomAD
CA400139483 rs1436012867	265	S>F		No	ClinGen gnomAD
CA400139482 rs780752557	266	V>L		No	ClinGen ExAC TOPMed gnomAD
rs780752557 CA8638191	266	V>M		No	ClinGen ExAC TOPMed gnomAD
rs750941681 CA8638189	268	L>F		No	ClinGen ExAC gnomAD
CA8638188 rs765667731	269	Q>*		No	ClinGen ExAC TOPMed gnomAD
rs1226953036 CA400139461	269	Q>H		No	ClinGen TOPMed
rs1286865235 CA400139447	272	Q>*		No	ClinGen TOPMed

No associated diseases with P35232

1 regional properties for P35232

Type	Name	Position	InterPro Accession
domain	Band 7 domain	26 - 205	IPR001107

Functions

		Description
EC Number
Subcellular Localization	Mitochondrion inner membrane Nucleus Cytoplasm Cell membrane
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

12 GO annotations of cellular component

Name	Definition
cell surface	The external part of the cell wall and/or plasma membrane.
cytoplasm	The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
early endosome	A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways.
extracellular exosome	A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm.
integral component of plasma membrane	The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
mitochondrial inner membrane	The inner, i.e. lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae.
mitochondrial prohibitin complex	A complex composed of two proteins, prohibitin 1 and prohibitin 2 (PHB1/PHB-1 and PHB2/PHB-2) that is highly conserved amongst eukaryotes and associated with the inner mitochondrial membrane. The mitochondrial prohibitin complex is a macromolecular supercomplex composed of repeating heterodimeric subunits of PHB1 and PHB2. The mitochondrial prohibitin complex plays a role in a number of biological processes, including mitochondrial biogenesis and function, development, replicative senescence, and cell death.
mitochondrion	A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration.
nucleoplasm	That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus	A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

8 GO annotations of molecular function

Name	Definition
complement component C3a binding	Binding to a C3a product of the complement cascade.
complement component C3b binding	Binding to a C3b product of the complement cascade.
enzyme binding	Binding to an enzyme, a protein with catalytic activity.
histone deacetylase binding	Binding to histone deacetylase.
protein C-terminus binding	Binding to a protein C-terminus, the end of a peptide chain at which the 1-carboxyl function of a constituent amino acid is not attached in peptide linkage to another amino-acid residue.
protein heterodimerization activity	Binding to a nonidentical protein to form a heterodimer.
proteinase activated receptor binding	Binding to a proteinase activated receptor.
transcription corepressor activity	A transcription coregulator activity that represses or decreases the transcription of specific gene sets via binding to a DNA-bound DNA-binding transcription factor, either on its own or as part of a complex. Corepressors often act by altering chromatin structure and modifications. For example, one class of transcription corepressors modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators.

39 GO annotations of biological process

Name	Definition
activation of phospholipase C activity	The initiation of the activity of the inactive enzyme phospolipase C as the result of The series of molecular signals generated as a consequence of a G protein-coupled receptor binding to its physiological ligand.
activation of protein kinase C activity	Any process that initiates the activity of the inactive enzyme protein kinase C.
antiviral innate immune response	A defense response against viruses mediated through an innate immune response. An innate immune response is mediated by germline encoded components that directly recognize components of potential pathogens.
B cell activation	The change in morphology and behavior of a mature or immature B cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific.
CD40 signaling pathway	The series of molecular signals initiated by the binding of the cell surface receptor CD40 to one of its physiological ligands, and ending with the regulation of a downstream cellular process, e.g. transcription.
cellular response to interleukin-6	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-6 stimulus.
DNA biosynthetic process	The biosynthetic process resulting in the formation of DNA.
histone deacetylation	The modification of histones by removal of acetyl groups.
mitochondrion organization	A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components.
modulation by host of viral RNA genome replication	A process in which a host organism modulates the frequency, rate or extent of viral RNA genome replication.
negative regulation of androgen receptor signaling pathway	Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway.
negative regulation of cell growth	Any process that stops, prevents, or reduces the frequency, rate, extent or direction of cell growth.
negative regulation of cell population proliferation	Any process that stops, prevents or reduces the rate or extent of cell proliferation.
negative regulation of DNA-templated transcription	Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription.
negative regulation of ERK1 and ERK2 cascade	Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
negative regulation of glucocorticoid receptor signaling pathway	Any process that stops, prevents or reduces the frequency, rate or extent of glucocorticoid receptor signaling pathway.
negative regulation of protein catabolic process	Any process that stops, prevents or reduces the frequency, rate or extent of protein catabolic process.
negative regulation of transcription by competitive promoter binding	Any process that stops, prevents, or reduces the frequency, rate or extent of DNA-dependent transcription using a mechanism that involves direct competition for interaction with a promoter binding site.
negative regulation of transcription by RNA polymerase II	Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II.
osteoblast differentiation	The process whereby a relatively unspecialized cell acquires the specialized features of an osteoblast, a mesodermal or neural crest cell that gives rise to bone.
positive regulation of cell death	Any process that increases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death.
positive regulation of complement activation	Any process that activates or increases the frequency, rate or extent of complement activation.
positive regulation of DNA-templated transcription	Any process that activates or increases the frequency, rate or extent of cellular DNA-templated transcription.
positive regulation of ERK1 and ERK2 cascade	Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
positive regulation of G protein-coupled receptor signaling pathway	Any process that activates or increases the frequency, rate or extent of G protein-coupled receptor signaling pathway activity.
positive regulation of gene expression	Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product (protein or RNA).
positive regulation of immunoglobulin production	Any process that activates or increases the frequency, rate, or extent of immunoglobulin production.
positive regulation of interleukin-17 production	Any process that activates or increases the frequency, rate, or extent of production of any member of the interleukin-17 family of cytokines.
positive regulation of NIK/NF-kappaB signaling	Any process that activates or increases the frequency, rate or extent of NIK/NF-kappaB signaling.
positive regulation of protein kinase B signaling	Any process that activates or increases the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.
positive regulation of smooth muscle cell proliferation	Any process that activates or increases the rate or extent of smooth muscle cell proliferation.
progesterone receptor signaling pathway	The series of molecular signals initiated by progesterone binding to its receptor in the cytoplasm.
protein stabilization	Any process involved in maintaining the structure and integrity of a protein and preventing it from degradation or aggregation.
regulation of apoptotic process	Any process that modulates the occurrence or rate of cell death by apoptotic process.
regulation of DNA-templated transcription	Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription.
RIG-I signaling pathway	The series of molecular signals initiated by the binding of viral RNA to a pattern recognition receptor (PRR) RIG-1 (also known as DDX58). RIG-I is a cytoplasmic receptor that detects RNA synthesized during viral replication and triggers a signaling pathway to protect the host against viral infection, for example by inducing the expression of antiviral cytokines.
signal transduction	The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.
T-helper 17 type immune response	An immune response which is associated with resistance to intracellular bacteria with a key role in inflammation and tissue injury. This immune response is associated with pathological autoimmune conditions such as multiple sclerosis, arthritis and psoriasis which is typically orchestrated by the production of particular cytokines by T-helper 17 cells, most notably interleukin-17, IL-21 and IL-22.
viral entry into host cell	The process that occurs after viral attachment by which a virus, or viral nucleic acid, breaches the plasma membrane or cell envelope and enters the host cell. The process ends when the viral nucleic acid is released into the host cell cytoplasm.

4 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q3T165	PHB1	Prohibitin 1	Bos taurus (Bovine)	PR
P84173	PHB1	Prohibitin 1	Gallus gallus (Chicken)	PR
Q9LK25	PHB4	Prohibitin-4, mitochondrial	Arabidopsis thaliana (Mouse-ear cress)	PR
Q9LY99	PHB5	Prohibitin-5, mitochondrial	Arabidopsis thaliana (Mouse-ear cress)	PR

10	20	30	40	50	60
MAAKVFESIG	KFGLALAVAG	GVVNSALYNV	DAGHRAVIFD	RFRGVQDIVV	GEGTHFLIPW
70	80	90	100	110	120
VQKPIIFDCR	SRPRNVPVIT	GSKDLQNVNI	TLRILFRPVA	SQLPRIFTSI	GEDYDERVLP
130	140	150	160	170	180
SITTEILKSV	VARFDAGELI	TQRELVSRQV	SDDLTERAAT	FGLILDDVSL	THLTFGKEFT
190	200	210	220	230	240
EAVEAKQVAQ	QEAERARFVV	EKAEQQKKAA	IISAEGDSKA	AELIANSLAT	AGDGLIELRK
250	260	270
LEAAEDIAYQ	LSRSRNITYL	PAGQSVLLQL	PQ